Search results
Showing 1751 to 1800 of 1968 results for news
Ground-breaking CAR-T therapy to treat aggressive form of blood cancer approved
More than 400 people set to benefit after NICE recommends first personalised immunotherapy for lymphoma.
New Chief Medical Officer, Chief People Officer and Director of Implementation and Partnerships appointed by NICE.
Adults with depression who want to quit antidepressants should be given support
Adults with depression who want to stop taking antidepressants should have the dose of their medication reduced in stages to reduce the likelihood and severity of withdrawal symptoms, NICE has said.
New treatment for advanced breast cancer recommended by NICE
Around 300 people are set to benefit following NICE’s recommendation of talazoparib for treating a type of locally advanced or metastatic breast cancer in final draft guidance published today (19 January 2024).
New one-a-day tablet for people with severe hair loss due to alopecia areata recommended by NICE
Public consultation on our new approach to prioritising guidance now open
The consultation seeks your views about our plans to make topic selection and prioritisation more integrated, effective and timely.
A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent womb cancer in final draft NICE guidance published today.
25,000 people to benefit after NICE recommends new ulcerative colitis treatment
New one-a-day pill recommended on the same day the treatment was granted a licence by the MHRA.
Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia.
New tests could spare people with early breast cancer from unnecessary chemotherapy
More people with early breast cancer could be spared chemotherapy and therefore avoid the side effects associated with the treatment after tumour profiling tests were recommended by NICE.
NICE and NHS England announce plan to enable innovative tech to be adopted quicker
NHS patients in England will benefit from faster access to the most innovative and cutting-edge medical technologies under new plans.
Home testing devices could increase the number of people diagnosed with sleep apnoea
Five home-testing devices to diagnose a silent sleep condition harming the health of an estimated 2.5 million adults have been recommended by NICE in draft guidance.
NICE's Early Value Assessment for Medtech: panning for nuggets of innovation gold
Early Value Assessment for Medtech and how it will offer a rapid assessment of digital products, devices and diagnostics for clinical effectiveness and value for money.
NICE Chairman, Sharmila Nebhrajani, today announced Dr Samantha Roberts as incoming Chief Executive.
Additional evidence needed to assess histology-independent cancer drugs
A paper published and co-authored by NICE staff looks at how histology-independent cancer drugs might be appraised.
NICE and NIHR: working together to produce research with impact
Alice and Zoe discuss how the National Institute of Health Research (NIHR) and NICE work in partnership and identify key research priorities from NICE guidance.
NICE has launched a free learning course that provides an introduction to health technology assessment (HTA).
Dr Roberts, who is a qualified doctor, has 20 years’ experience in clinical and management posts in healthcare both in the private and public sector.
New functionality for online collaboration on consultations, enables groups or organisations to submit a joined-up response.
Patient safety and surgical innovation – why new isn't always better
Jane Blazeby, Professor of Surgery, University of Bristol, University Hospitals Bristol and Weston and the NIHR Bristol Biomedical Research Centre, talks about the research she’s led to explore and address optimism bias and other issues in surgical innovation.
Children and young people need accurate, accessible information about their healthcare
New draft guidance from NICE recommends children and young people are fully informed about their health so that they can take an active role in their healthcare.
Angela sets out to understand some of the challenges, benefits and considerations of setting up and running a virtual ward, from the perspective of teams on the front lines.
Working in partnership to harness the potential of digital technology
Nicola Bent talks about NICE and the AHSN Network’s important ambition to address market access challenges for digital innovation as part of the collaboration agreement.
A new treatment that increases the chance of a successful kidney transplant has been recommended by NICE in final draft guidance.
As we launch an early version of the online service, mapping out the regulatory and health technology assessment pathway, Ciara Cook invites future users to help shape this exciting new initiative.
A refreshed Evidence Standards Framework for Digital Health Technologies
Two exciting developments which will accelerate NICE’s efforts to deliver innovation to the health and care system faster.
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
NICE has issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.
NICE has outlined what aspects of menopause care will be updated in upcoming guidance, including areas where more research is needed.
How NICE is helping to build the role of the NHS on the global stage
Kevin Miles discusses how NICE International is working to shape and improve health and care systems at home and abroad as part of the NHS Consortium for Global Health.
Dr Ravinder Claire outlines recent progress towards greater use of real-world evidence in regulatory decision-making. He also considers the implications and opportunities for NICE and our stakeholders.
NICE's flexibility in evaluation of new health tech and fairer patient access
Changes to the way medicines and other health technologies are evaluated by NICE for use in the NHS were approved by its Board.
Celebrating the people who support NICE: International Volunteer Day
Applauding the members of the public who donate their valuable experience and insight to NICE.
NICE to become single point of access for Covid-19 guidance and advice
NICE announced that it is to host a new, single point of advice on caring for people with Covid-19 and the management of Covid-19 in a variety of clinical settings.
NICE is making changes to simplify our offer to the life sciences industry.
NICE announces start of review of nusinersen Managed Access Agreement
NICE has today (29 October 2020) announced that it has begun the process to review data collected as part of the Managed Access Agreement (MAA) for nusinersen.
How we can offer a broader range of benefits for people, their families and carers
NICE has been part of a research project investigating how quality of life measures used to evaluate healthcare treatments such as drugs can be extended into areas of social care and public health.
In April 2021, the National Institute for Health Research (NIHR) launched a new rolling funding call for studies addressing NICE research recommendations.
NICE approves life-changing gene therapy for treating spinal muscular atrophy
A new one-off gene therapy for babies with the rare genetic disorder spinal muscular atrophy (SMA) is set to become the most expensive treatment ever approved by NICE.
Harriet Unsworth outlines her role in updating our evidence standards framework for digital health technologies. She also explains how you can share your views as part of our consultation.
How is NICE supporting digital health technology developers?
Richard Chivers, operations manager for NICE Scientific Advice, looks at how we’re supporting digital health technology developers and helping them with some of the challenges around evidence requirements and adoption within the NHS.
Self-harm is everyone's business, NICE says in new draft guideline
All professionals working across the health and social care system have a role to play in supporting people who self-harm and the issue should not just be seen as the responsibility of those with mental health expertise, NICE has said in a new draft guideline.
Using our guidance and resources in continuing professional development (CPD)
Registered social workers must demonstrate the use of evidence and research to inform their practice in order to meet professional standards. This is echoed in Social Work England’s continuing professional development (CPD) standards.
Increasing the capacity of our technology appraisals - the proportionate way
Jenniffer Prescott describes how we are trialling a proportionate approach to technology appraisals, which we expect will increase our capacity by 20% from 2023/24.
Pilar Pinilla-Dominguez reveals how NICE, through its international collaborations and partnerships, aims to contribute to improvements in health and care outcomes across the world, bringing learnings and benefits back to NICE, the NHS and the wider UK health and care system.
NICE calls for further research into the treatment of chronic lipoedema
NICE has today issued interventional procedures guidance on the use of liposuction for the treatment of chronic lipoedema.
Working at the forefront of neurodegenerative disease research
Claire Hawksworth reveals NICE’s role in a global partnership to better understand neurodegenerative conditions and speed up delivery of innovative treatments.
Dr Sam Roberts, chief executive of NICE, celebrates the NHS on its 75th anniversary. She discusses how NICE has supported the NHS with its recent achievements. She also highlights how NICE is evolving; through driving value-based healthcare to support the NHS as it adapts to meet current challenges.
To mark Time to Talk Day (February 2) we spoke with Catherine Ruane, who acted as a carer for her father and sister, who both lived with depression.
NICE guidance addresses the best approach to the diagnosis and management of ME/CFS
NICE has today (10 November 2020) published its draft guideline on the diagnosis and management of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Pembrolizumab plus chemotherapy not recommend for triple negative breast cancer
Draft guidance published today (8 March 2022) by NICE does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer